Filter posts

Delivering on the Promise of Personalized Medicine

As sequencing moves out of the lab and into the clinic, a host of players …

Pharmaceuticals Play a Key Role in Value-Based Care

By Dan Leonard, President, National Pharmaceutical Council Public and private sector health care stakeholders have …

Mayo v. Prometheus: Thought Leaders Express Concern and Evaluate the Impact

The Mayo v. Prometheus event hosted at George Washington School of Law with the Biotechnology …

Patent-Eligible Subject Matter after Mayo v. Prometheus: Exploring the Path Forward

Patent-Eligible Subject Matter after Mayo v. Prometheus: Exploring the Path Forward is a public round-table event hosted …

BIO's Prometheus v. Mayo Amicus Brief Filed

BIO filed an amicus brief in the Prometheus v. Mayo Clinic case.  In this case …

BIO's New Personalized Medicine and Diagnostics Working Group

The Biotechnology Industry Organization (BIO) represents a diverse portfolio of companies throughout the continuum of …

Myriad Genetics' actions justify a ban on gene patents?

The following information was provided by Myriad’s General Counsel during his presentation on the subject …

Intellectual Property problems for personalized medicine

Amid growing interest in personalized medicine that stands to provide patients with better care at …